FDA defends biotech review process

A Center for Science in the Public Interest study suggests the FDA missed "obvious errors" in reviewing some gene-altered crops. According to CSPI, the FDA's procedures are filled with holes and as a result, continued safety of genetically engineered plants cannot be ensured. The FDA says it has always been open to changing its review process if new biotech products demand greater scrutiny.

View Full Article in:

Washington Post (tiered subscription model), The · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC